EMA Authorised: Sylvant (siltuximab) — Recordati Netherlands B.V.

View source ↗

Summary

Authorised status for Sylvant (siltuximab) in the EU for the therapeutic area of Giant Lymph Node Hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Lymph Node Hyperplasia

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Status: Authorised. Therapeutic area: Giant Lymph Node Hyperplasia. MAH: Recordati Netherlands B.V.. Decision date: 28/07/2026. Accelerated assessment